Skip to content
DeepViews

Organon & Co. (OGN) — 分析摘要

Organon & Co.(OGN)的市值为3.58十亿美元,最近一年的营收同比增长了-2.9%。净利润率为3.0%。当前市盈率为17.2倍。

核心要点

  • 营收同比变化-2.9%
  • 净利润率3.0%
  • 市盈率17.2倍

与PHARMACEUTICAL PREPARATIONS板块的其他公司相比,OGN的营收增长为-2.9%,市盈率为17.2倍。

[XNYS]

Organon & Co. (OGN)

$13.65

更新 — ET · 市场数据 POLYGON · 财务数据 SEC EDGAR

市值
$3584.62M
企业价值
$11.01B
市盈率
17.2
股息率
0.59%
EV/EBITDA
9.8
公司简介
关于
关于 Organon & Co.

Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.

行业

PHARMACEUTICAL PREPARATIONS

员工人数

10,000

总部

JERSEY CITY, NJ

Exchange

XNYS

官网
Source: Polygon.io
评分
竞争壁垒
竞争壁垒
39
无护城河

基于 4 年财务数据的系统性竞争优势评估

此评估基于历史财务数据的量化分析,不构成投资建议。护城河评级可能随行业和竞争环境变化。

市场信号
估值
盈利
内部人交易
内部人备案活动

首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。

加载 SEC 内部人备案数据...
超级投资者
财务健康
财务健康

资本结构

总权益$1006.00M
总债务$8553.00M
债务权益比8.50
现金及等价物$1132.00M

现金流

经营现金流$737.00M
自由现金流$567.00M
自由现金流率9.25%
P/FCF 比率6.32
Source: Polygon.io · SEC EDGAR
股息
股息

年度每股股息

$0.08

股息收益率

0.59%

季度
最近除息日: 2026-08-14

股息历史

2026-08-14
CD$0.0200
2026-05-11
CD$0.0200
2026-02-23
CD$0.0200
2025-11-20
CD$0.0200
Source: Polygon.io
最新资讯
Recent News

免责声明:本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。